{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:33:41Z","timestamp":1790264021763,"version":"4.1.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Outbreaks of Ebolaviruses, such as Sudanvirus (SUDV) in Uganda in 2022, demonstrate that species other than the Zaire ebolavirus (EBOV), which is currently the sole virus represented in current licensed vaccines, remain a major threat to global health. There is a pressing need to develop effective pan-species vaccines and novel monoclonal antibody-based therapeutics for Ebolavirus disease. In response to recent outbreaks, the two dose, heterologous Ad26.ZEBOV\/MVA-BN-Filo vaccine regimen was developed and was tested in a large phase II clinical trial (EBL2001) as part of the EBOVAC2 consortium. Here, we perform bulk sequencing of the variable heavy chain (VH) of B cell receptors (BCR) in forty participants from the EBL2001 trial in order to characterize the BCR repertoire in response to vaccination with Ad26.ZEBOV\/MVA-BN-Filo. We develop a comprehensive database, EBOV-AbDab, of publicly available Ebolavirus-specific antibody sequences. We then use our database to predict the antigen-specific component of the vaccinee repertoires. Our results show striking convergence in VH germline gene usage across participants following the MVA-BN-Filo dose, and provide further evidence of the role of IGHV3\u201315 and IGHV3\u201313 antibodies in the B cell response to Ebolavirus glycoprotein. Furthermore, we found that previously described Ebola-specific mAb sequences present in EBOV-AbDab were sufficient to describe at least one of the ten most expanded BCR clonotypes in more than two thirds of our cohort of vaccinees following the boost, providing proof of principle for the utility of computational mining of immune repertoires.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1383753","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T04:25:21Z","timestamp":1720412721000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination"],"prefix":"10.3389","volume":"15","author":[{"given":"Eve","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagida","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Schimanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Rijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ghraichy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"von Niederh\u00e4usern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Tr\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Clutterbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Luhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte M.","family":"Deane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic F.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"150019","DOI":"10.1038\/sdata.2015.19","article-title":"A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making","volume":"2","author":"Van Kerkhove","year":"2015","journal-title":"Sci Data"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-018-0227-2","article-title":"Discovery of a new ebolavirus (Bombali virus) in molossid bats in Sierra Leone","volume":"3","author":"Goldstein","year":"2018","journal-title":"Nat Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz267","article-title":"Is the Bombali virus pathogenic in humans","volume":"35","author":"Martell","year":"2019","journal-title":"Bioinformatics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.015","article-title":"Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein","volume":"54","author":"Misasi","year":"2021","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","first-page":"20160308","DOI":"10.1098\/rstb.2016.0308","article-title":"Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013\u20132016","volume":"372","author":"Garske","year":"2017","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"20160293","DOI":"10.1098\/rstb.2016.0293","article-title":"The contribution of biological, mathematical, clinical, engineering and social sciences to combatting the West African Ebola epidemic","volume":"372","author":"Whitty","year":"2017","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00416-8","article-title":"The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats","volume":"16","author":"Osterholm","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomized, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomized stage 1, and a randomized, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomized, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomized, placebo-controlled, multicenter Phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PloS Med"},{"key":"B13","unstructured":"European medicines agency2024"},{"key":"B14","unstructured":"European medicines agency2024"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of clinical-stage human monoclonal antibodies that treat advanced ebola virus disease in nonhuman primates","volume":"218","author":"Pascal","year":"2018","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1915350","article-title":"Monoclonal antibody therapy for ebola virus disease","volume":"381","author":"Levine","year":"2019","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.coviro.2023.101339","article-title":"A review of broadly protective monoclonal antibodies to treat Ebola virus disease","volume":"61","author":"Rijal","year":"2023","journal-title":"Curr Opin Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.12.004","article-title":"Development of a human antibody cocktail that deploys multiple functions to confer pan-Ebolavirus protection","volume":"25","author":"Wec","year":"2019","journal-title":"Cell Host Amp Microbe"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1086\/514280","article-title":"Recombinant human monoclonal antibodies to ebola virus","volume":"179","author":"Maruyama","year":"1999","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2002.1533","article-title":"Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay","volume":"300","author":"Meissner","year":"2002","journal-title":"Virology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.celrep.2021.108984","article-title":"Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies","volume":"35","author":"Murin","year":"2021","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","article-title":"Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein","volume":"49","author":"Gilchuk","year":"2018","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01439\u201318","article-title":"Early human B cell response to ebola virus in four U.S. Survivors of infection","volume":"93","author":"Williamson","year":"2019","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.706757","article-title":"Proteo-genomic analysis identifies two major sites of vulnerability on ebolavirus glycoprotein for neutralizing antibodies in convalescent human plasma","volume":"12","author":"Gilchuk","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cell.2022.02.023","article-title":"Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses","volume":"185","author":"Milligan","year":"2022","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"112370","DOI":"10.1016\/j.celrep.2023.112370","article-title":"Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes","volume":"42","author":"Chen","year":"2023","journal-title":"Cell Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","article-title":"Therapeutic monoclonal antibodies for ebola virus infection derived from vaccinated humans","volume":"27","author":"Rijal","year":"2019","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0602-4","article-title":"Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV","volume":"25","author":"Ehrhardt","year":"2019","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against ebola virus GP defines features that contribute to protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1006","article-title":"The immune epitope database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad1056","article-title":"The Patent and Literature Antibody Database (PLAbDab): an evolving reference set of functionally diverse, literature-annotated antibody sequences and structures","volume":"52","author":"Abanades","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt382","article-title":"IgBLAST: an immunoglobulin variable domain sequence analysis tool","volume":"41","author":"Ye","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn838","article-title":"IMGT\u00ae, the international ImMunoGeneTics information system\u00ae","volume":"37","author":"Lefranc","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab1136","article-title":"IMGT\u00ae databases, related tools and web resources through three main axes of research and development","volume":"50","author":"Manso","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/bioinformatics\/btv552","article-title":"ANARCI: antigen receptor numbering and receptor classification","volume":"32","author":"Dunbar","year":"2016","journal-title":"Bioinformatics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa739","article-title":"CoV-AbDab: the coronavirus antibody database","volume":"37","author":"Raybould","year":"2021","journal-title":"Bioinformatics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv404","article-title":"CATNAP: a tool to compile, analyze and tally neutralizing antibody panels","volume":"43","author":"Yoon","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01734","article-title":"Maturation of the human immunoglobulin heavy chain repertoire with age","volume":"11","author":"Ghraichy","year":"2020","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu138","article-title":"pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires","volume":"30","author":"Vander Heiden","year":"2014","journal-title":"Bioinformatics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv359","article-title":"Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data","volume":"31","author":"Gupta","year":"2015","journal-title":"Bioinformatics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1101\/gr.111120.110","article-title":"Stampy: A statistical algorithm for sensitive and fast mapping of Illumina sequence reads","volume":"21","author":"Lunter","year":"2011","journal-title":"Genome Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.25080\/Majora-92bf1922-011","article-title":"Statsmodels: econometric and statistical modeling with python","author":"Seabold","year":"2010"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1869406","DOI":"10.1080\/19420862.2020.1869406","article-title":"A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-pertussis toxoid antibodies","volume":"13","author":"Richardson","year":"2021","journal-title":"mAbs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad1056","article-title":"The Patent and Literature Antibody Database (PLAbDab): an evolving reference set of functionally diverse, literature-annotated antibody sequences and structures","volume":"52","author":"Abanades","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.01.007","article-title":"Structural basis for a convergent immune response against ebola virus","volume":"27","author":"Cohen-Dvashi","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113366","article-title":"The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus","volume":"42","author":"Yu","year":"2023","journal-title":"Cell Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00110","article-title":"Can we improve vaccine efficacy by targeting T and B cell repertoire convergence","volume":"10","author":"Fink","year":"2019","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605170","article-title":"Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures","volume":"11","author":"Galson","year":"2020","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"113101","DOI":"10.1016\/j.celrep.2023.113101","article-title":"Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV\/MVA-BN-Filo","volume":"42","author":"Blengio","year":"2023","journal-title":"Cell Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.04.036","article-title":"Longitudinal analysis of the human B cell response to ebola virus infection","volume":"177","author":"Davis","year":"2019","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2019.02.004","article-title":"VH1\u201369 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design","volume":"34","author":"Chen","year":"2019","journal-title":"Curr Opin Virol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1038\/s41467-023-40070-x","article-title":"Genetic variation in the immunoglobulin heavy chain locus shapes the human antibody repertoire","volume":"14","author":"Rodriguez","year":"2023","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2023.05.003","article-title":"Untangling associations between immunoglobulin genotypes, repertoires and function","volume":"259","author":"Castro Dopico","year":"2023","journal-title":"Immunol Lett"},{"key":"B59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41541-024-00811-5","article-title":"Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming","volume":"9","author":"deCamp","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2023.11.01.565093","DOI":"10.1101\/2023.11.01.565093v1","article-title":"Benchmarking and integrating human B-cell receptor genomic and antibody proteomic profiling [Internet]","author":"Qu\u00fd","year":"2023","journal-title":"bioRxiv"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317793111","article-title":"Identification and characterization of the constituent human serum antibodies elicited by vaccination","volume":"111","author":"Lavinder","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.05.013","article-title":"Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements","volume":"16","author":"Jackson","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401405","article-title":"Identification of antigen-specific B cell receptor sequences using public repertoire analysis","volume":"194","author":"Tr\u00fcck","year":"2015","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1135841","article-title":"Convergent antibody responses are associated with broad neutralization of hepatitis C virus","volume":"14","author":"Skinner","year":"2023","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2022.03.019","article-title":"A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2","volume":"55","author":"Wang","year":"2022","journal-title":"Immunity"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1010052","DOI":"10.1371\/journal.pcbi.1010052","article-title":"AIRRscape: An interactive tool for exploring B-cell receptor repertoires and antibody responses","volume":"18","author":"Waltari","year":"2022","journal-title":"PloS Comput Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807104","article-title":"endemic: B cell repertoire analysis reveals unique anti-viral responses to SARS-coV-2, ebola and respiratory syncytial virus","volume":"13","author":"Stewart","year":"2022","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.chom.2013.05.008","article-title":"Convergent antibody signatures in human dengue","volume":"13","author":"Parameswaran","year":"2013","journal-title":"Cell Host Microbe"},{"key":"B69","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","article-title":"Recurrent potent human neutralizing antibodies to zika virus in Brazil and Mexico","volume":"169","author":"Robbiani","year":"2017","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/science.adc9498","article-title":"Germline-encoded amino acid\u2013binding motifs drive immunodominant public antibody responses","volume":"380","author":"Shrock","year":"2023","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2023.09.06.556442","DOI":"10.1101\/2023.09.06.556442v1","article-title":"Convergent sequence features of antiviral B cells","author":"Abu-Shmais","year":"2023","journal-title":"bioRxiv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1383753\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T04:25:26Z","timestamp":1720412726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1383753\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":71,"alternative-id":["10.3389\/fimmu.2024.1383753"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1383753","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"article-number":"1383753"}}